Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib DDI with Dabigatran in Healthy Volunteers
NCT04782076Phase 1Completed
- Sponsor
- Loxo Oncology
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selpercatinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC) and thyroid cancer, sponsored by Loxo Oncology. Primary endpoints: Maximum Concentration of Dabigatran and Area Under the Concentration Versus Time Curve From Time Zero to Infinity of Dabigatran at Day 8. Started Mar 2021; status: completed.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)thyroid cancer
Beyond the preview
Go deeper on NCT04782076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782076.